Related Experiment Video
Updated: Jun 4, 2026
Static Adhesion Assay for the Study of Integrin Activation in T Lymphocytes
Published on: June 13, 2014
Heterotypic cell adhesion assay for the study of cell adhesion inhibition
Seetharama D Satyanarayanajois1, Sharon Ronald, Jining Liu
1Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA. jois@ulm.edu
Insights
This study introduces a rapid lymphocyte-epithelial assay to measure CD2-CD58 interactions, offering a safer alternative to traditional methods for evaluating autoimmune disease therapies.
Area of Science:
- Immunology
- Cell Biology
- Biochemistry
Background:
- CD2-CD58 interaction is crucial for T-cell activation and immune recognition.
- Modulating this interaction shows therapeutic potential for autoimmune diseases.
- Current methods like E-rosetting assays are labor-intensive and potentially hazardous.
Purpose of the Study:
- To describe and validate a novel, rapid, and sensitive cell adhesion assay.
- To evaluate the inhibitory activity of small molecules and peptides on CD2-CD58 interactions.
- To provide an alternative to hazardous E-rosetting assays for studying cell adhesion inhibition.
Main Methods:
- Development and application of a lymphocyte-epithelial cell adhesion assay.
- Utilizing Jurkat cells (expressing CD2) and Caco-2 cells (expressing CD58).
- Confirmation of cell surface expression via flow cytometry and ELISA.
Main Results:
- The lymphocyte-epithelial assay is a rapid (under 4 hours) and sensitive method.
- The assay effectively evaluates the inhibitory effects of peptides and small molecules.
- Confirms the utility of Jurkat and Caco-2 cells for studying CD2-CD58 interactions.
Conclusions:
- The described lymphocyte-epithelial assay is a valuable tool for studying CD2-CD58 interactions.
- This assay offers a safer and more efficient alternative for drug discovery in autoimmune diseases.
- The assay facilitates the evaluation of novel therapeutics targeting cell adhesion molecules.
Abstract:
CD2 is a cell adhesion molecule that mediates T-cell activation by binding to its ligand CD58 on antigen-presenting cells. Interaction between CD2 and CD58 or leukocyte function-associated antigen-3 (LFA-3) helps to optimize immune recognition facilitating contact between T lymphocytes and antigen-presenting cells. Modulation or inhibition of this interaction has been shown to be therapeutically useful in the treatment of autoimmune diseases. Antibodies and small molecules including peptides have been designed to modulate or disrupt the cell adhesion interactions due to CD2 and CD58. E-rosetting assay is a widely used method applied in the study of the modulation of CD2-CD58 interaction, which is either labor-intensive or radio-hazardous. In this chapter, we describe two methods that are used to study cell adhesion inhibition: (a) E-rosetting Assay and (b) Lymphocyte-epithelial assay. The second method, lymphocyte-epithelial assay, is a rapid and sensitive heterotypic cell adhesion assay for studying cell adhesion inhibition. The method relies on the CD2 expression on the surface of Jurkat cells and the CD58 expression on the surface of Caco-2 cells, which were confirmed by flow cytometry and ELISA studies respectively. This heterotypic cell adhesion assay described typically takes less than 4 h to perform, allows the evaluation of inhibitory activity of peptides/small molecules to modulate CD2-CD58 interaction in real cell system.
